Immunotherapy Toxicity Management in Bladder Cancer
Immunotherapy Toxicity Management in Bladder Cancer
Panelists Daniel P. Petrylak, MD; Dean F. Bajorin, MD; Arjun V. Balar, MD; Elizabeth R. Plimack, MD, MS; and Robert Dreicer, MD, MS, discuss immune-related toxicities associated with checkpoint inhibitors and what to look out for in patients with advanced bladder cancer.
Immunotherapy News from China
- UPDATE 2-U.S. FDA approves Merck immunotherapy/chemo combo …
- …Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to…
- UPDATE 2-U.S. FDA approves Merck immunotherapy/chemo combo …
- …in Combination With Anti-PD-L1 Cancer Immunotherapy and …
- …Dosed in First-in-Human Clinical Study of Immunotherapy …
- JITC tumor and cancer immunotherapy papers collection
- Welcome to the submission|Journal for ImmunoTherapy of Cancer
- Immunotherapy shows promise for advanced lymphoma: study
- …from the Monotherapy Arm at the Phacilitate Immunotherapy …
- Allergy Immunotherapy Market to exceed US$ 3.33 Bn by 2025 …
Leave a Reply
You must be logged in to post a comment.